Cargando…

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data

SIMPLE SUMMARY: We studied determinants of response to immune-checkpoint inhibition in advanced non-small cell lung cancer patients. Specifically, we evaluated the association with response of multiple simple pre-treatment blood markers available from routine examination. We first used classical sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benzekry, Sébastien, Grangeon, Mathieu, Karlsen, Mélanie, Alexa, Maria, Bicalho-Frazeto, Isabella, Chaleat, Solène, Tomasini, Pascale, Barbolosi, Dominique, Barlesi, Fabrice, Greillier, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699503/ https://www.ncbi.nlm.nih.gov/pubmed/34944830 http://dx.doi.org/10.3390/cancers13246210

Ejemplares similares

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016)

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
por: Tomasini, Pascale, et al.
Publicado: (2019)

Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
por: Bilous, M., et al.
Publicado: (2019)

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma
por: Imbs, Diane‐Charlotte, et al.
Publicado: (2017)

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
por: Barlesi, Fabrice, et al.
Publicado: (2017)

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
por: Boyer, Arnaud, et al.
Publicado: (2018)

Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC
por: Ciccolini, Joseph, et al.
Publicado: (2020)

Immunologically effective dose: a practical model for immuno-radiotherapy
por: Serre, Raphaël, et al.
Publicado: (2018)

The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer
por: Mogenet, Alice, et al.
Publicado: (2021)

Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy
por: Jean, Fanny, et al.
Publicado: (2017)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer
por: Tomasini, Pascale, et al.
Publicado: (2016)

Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis
por: Mollard, Severine, et al.
Publicado: (2017)

COVID-19 et cancer bronchique : adaptation des schémas d’immunothérapie et qualité de vie
por: Travert, C., et al.
Publicado: (2021)

Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer
por: Couderc, Anne-Laure, et al.
Publicado: (2022)

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023)

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
por: Elharrar, Xavier, et al.
Publicado: (2016)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients
por: Faivre, C, et al.
Publicado: (2017)

Medication Reconciliation Associated with Comprehensive Geriatric Assessment in Older Patients with Cancer: ChimioAge Study
por: Couderc, Anne-Laure, et al.
Publicado: (2020)

Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy
por: Sicard, Guillaume, et al.
Publicado: (2020)

Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study
por: Tomasini, Pascale, et al.
Publicado: (2020)

Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer
por: Gouton, Etienne, et al.
Publicado: (2022)

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
por: Demerlé, Clémence, et al.
Publicado: (2023)

Global Dormancy of Metastases Due to Systemic Inhibition of Angiogenesis
por: Benzekry, Sébastien, et al.
Publicado: (2014)

Mechanistic models for hematological toxicities: Small is beautiful
por: Deyme, Laure, et al.
Publicado: (2021)

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
por: Ghiringhelli, François, et al.
Publicado: (2023)

Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: Further step in understanding hereditary tumor differences and future therapeutic strategies
por: Barbolosi, Dominique, et al.
Publicado: (2018)

Tumor growth monitoring in breast cancer xenografts: A good technique for a strong ethic
por: Rodallec, Anne, et al.
Publicado: (2022)

Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Carroll, Christina S E, et al.
Publicado: (2021)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
por: Cautela, Jennifer, et al.
Publicado: (2020)

Domains of quality of life freely expressed by cancer patients and their caregivers: contribution of the SEIQoL
por: Hamidou, Zeinab, et al.
Publicado: (2017)

In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling
por: Mollard, Séverine, et al.
Publicado: (2016)

Immunotherapy in Renal Cell Carcinoma: The Future Is Now
por: Deleuze, Antoine, et al.
Publicado: (2020)

Positivity made simple
por: Isabella, Giulia
Publicado: (2023)

A new methodology to derive 3D kinetic parametric FDG PET images based on a mathematical approach integrating an error model of measurement
por: Colard, Elyse, et al.
Publicado: (2018)

Isokinetic trunk strength in the teenagers with and without low-back pain: a comparative study
por: Bernard, JC, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_kreuerqfndr995t6430s0eabtq